润都股份(002923.SZ)：硫酸氨基葡萄糖氯化钠复盐获得化学原料药上市申请批准通知书

Core Insights - Rundu Co., Ltd. (002923.SZ) has received approval from the National Medical Products Administration for the marketing application of Glucosamine Sulfate Sodium Chloride Compound, which is indicated for the treatment of primary and secondary osteoarthritis [1] Group 1 - The product is specifically designed for treating osteoarthritis, a common joint condition [1] - The approval signifies a potential growth opportunity for the company in the pharmaceutical market [1]